Journal of Antimicrobial Chemotherapy (1987) 20, 95-107
© 1987 The British Society for Antimicrobial Chemotherapy
research-article |
A prospective randomized trial of ceftazidime versus cefazolin/tobramycin in the treatment of hospitalized patients with pneumonia
aDivision of Infectious Disease, McMaster University Hamilton, Ontario bDivision of Infectious Disease, University of Calgary Calgary, Alberta cDepartment of Medical Microbiology, University of Manitoba Winnipeg, Manitoba dDivision of Infectious Disease, McMaster University Hamilton, Ontario gDepartments of Experimental Medicine, Microbiology and Immunology, McGill University Montreal, Quebec hDivision of Infectious Diseases, University of Toronto Toronto, Ontario iDepartment of Microbiology, St.-Luc Hospital Montreal, Quebec jDivision of Infectious Diseases, University of Toronto Toronto, Ontario kDivision of Infectious Diseases, University of Alberta Edmonton, Alberta, Canada
accepted 10 January 1987
Ceftazidime and cefazolin/tobramycin were compared in the treatment of hospitalized patients with pneumonia. Iv doses 8-hourly were: ceftazidime—2 g, cefazolin—1.5 g, tobramycin—1.7 mg/kg. For patients with pseudomonas infection randomized to cefazolin/tobramycin, ticarcillin (3 g iv 4-hourly) was used instead of cefazolin. One hundred and ten of 129 patients were evaluable (ceftazidime = 52, cefazolin/tobramycin = 58). Seventy five cases (68%) had documented pathogens of which 81% were aerobic Gram-negative bacilli. Analysis of clinical response showed no difference in overall results (P =0.77), or separate outcomes: cured (P = 0.85), improved (P = 0.62), failed (P = 0.53), or relapsed (P = 0.50). No differences in bacteriological response were noted either: eradication (P > 0.10), elimination with recurrence (P > 0.l0), persistence (P > 0.l0). The incidence of enterococcal and fungal colonization and supermfection was the same for both regimens. There was a greater incidence of Coombs' test positivity with ceftazidime (P > 0.01) but greater nephrotoxicity with cefazolin/tobramycin (P > 0.02). Ceftazidime appears to be as eflicacious as cefazolin/tobramycin in the treatment of hospitalized patients with pneumonia, and is less nephrotoxic.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. G. Masterton, A. Galloway, G. French, M. Street, J. Armstrong, E. Brown, J. Cleverley, P. Dilworth, C. Fry, A. D. Gascoigne, et al. Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the Working Party on Hospital-Acquired Pneumonia of the British Society for Antimicrobial Chemotherapy J. Antimicrob. Chemother., July 1, 2008; 62(1): 5 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Paul, I. Benuri-Silbiger, K. Soares-Weiser, and L. Leibovici {beta} lactam monotherapy versus {beta} lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials BMJ, March 20, 2004; 328(7441): 668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Chastre and J.-Y. Fagon Ventilator-associated Pneumonia Am. J. Respir. Crit. Care Med., April 1, 2002; 165(7): 867 - 903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Jaccard, N. Troillet, S. Harbarth, G. Zanetti, D. Aymon, R. Schneider, R. Chiolero, B. Ricou, J. Romand, O. Huber, et al. Prospective Randomized Comparison of Imipenem-Cilastatin and Piperacillin-Tazobactam in Nosocomial Pneumonia or Peritonitis Antimicrob. Agents Chemother., November 1, 1998; 42(11): 2966 - 2972. [Abstract] [Full Text]
|
|